Profile data is unavailable for this security.
About the company
Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas, and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.
- Revenue in NZD (TTM)24.00m
- Net income in NZD-31.65m
- Incorporated2001
- Employees0.00
- LocationPacific Edge LtdCentre for Innovation 87 St David St,PO Box 56DUNEDIN 9016New ZealandNZL
- Phone+64 34795800
- Fax+64 34795801
- Websitehttps://www.pacificedgedx.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PuraPharm Corp Ltd | 87.54m | -22.83m | 63.89m | 662.00 | -- | 1.91 | -- | 0.7201 | -0.2685 | -0.2685 | 1.03 | 0.3871 | 0.4374 | 1.04 | 4.19 | 614,590.60 | -11.40 | -9.20 | -34.00 | -19.70 | 53.24 | 59.44 | -26.07 | -19.33 | 0.3046 | -2.28 | 0.7349 | -- | -9.20 | -11.41 | 11.76 | -- | -13.68 | -- |
| Take Solutions Ltd | 17.22m | -2.30m | 66.02m | 211.00 | -- | -- | -- | 3.89 | -0.7833 | -4.44 | 5.90 | -- | -- | -- | -- | 4,031,915.00 | -- | -4.65 | -- | -7.25 | 55.38 | 71.04 | -13.49 | -7.07 | -- | 1.07 | -- | -- | -71.03 | -34.66 | 43.41 | -- | -44.31 | -- |
| Pacific Edge Ltd | 24.00m | -31.65m | 66.52m | 0.00 | -- | 0.9852 | -- | 2.81 | -0.0393 | -0.0393 | 0.0298 | 0.0843 | 0.2623 | -- | 4.27 | -- | -34.58 | -41.14 | -37.52 | -45.47 | -- | -- | -131.84 | -208.27 | 9.78 | -- | 0.0203 | -- | 71.39 | 41.98 | -36.27 | -- | 54.08 | -- |
| Biotron Ltd | 1.80m | -4.40m | 67.08m | 4.00 | -- | 33.30 | -- | 37.84 | -0.0045 | -0.0045 | 0.0018 | 0.0021 | 0.3587 | -- | -- | -- | -87.73 | -64.30 | -103.46 | -74.43 | -156.30 | -108.03 | -244.54 | -231.62 | -- | -- | 0.0148 | -- | -8.16 | -2.48 | -25.59 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Harbour Asset Management Ltd.as of 04 Dec 2023 | 113.84m | 14.03% |
| ANZ New Zealand Investments Ltd.as of 07 Dec 2023 | 78.69m | 9.70% |
| BT Funds Management (NZ) Ltd.as of 31 Mar 2023 | 52.81m | 6.51% |
| Salt Funds Management Ltd.as of 31 Mar 2023 | 48.11m | 5.93% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 18.52m | 2.28% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 1.78m | 0.22% |
| FCA Corp.as of 29 Feb 2024 | 800.00k | 0.10% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 132.78k | 0.02% |
| DFA Australia Ltd.as of 29 Feb 2024 | 83.37k | 0.01% |
| Guardians of New Zealand Superannuationas of 30 Jun 2023 | 0.00 | 0.00% |
